| 1.8 -0.005 (-0.28%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.35 | 1-year : | 2.61 |
| Resists | First : | 2.01 | Second : | 2.24 |
| Pivot price | 1.82 |
|||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.86 |
MA(20) : | 1.84 |
| MA(100) : | 2.38 |
MA(250) : | 2.53 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.4 |
D(3) : | 54.3 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 3.83 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NRXP ] has closed above bottom band by 36.7%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.72 - 1.74 | 1.74 - 1.75 |
| Close: | 1.78 - 1.8 | 1.8 - 1.82 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Tue, 03 Mar 2026
NRXP: HC Wainwright & Co. Raises Price Target Amid Sustained 'Bu - GuruFocus
Mon, 02 Mar 2026
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer - Digital Journal
Mon, 02 Mar 2026
NRx Pharmaceuticals (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway - Digital Journal
Mon, 02 Mar 2026
NRx Pharmaceuticals Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Investing News Network
Mon, 02 Mar 2026
Harvard brain-stimulation leader joins NRx to target PTSD, depression - Stock Titan
Sun, 01 Mar 2026
NRXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.976e+007 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.52e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 701.6 % |
| Return on Equity (ttm) | -97.9 % |
| Qtrly Rev. Growth | 242000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 73979.6 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.8 |
| Dividend | 0 |
| Forward Dividend | 2.78e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|